CATALOGO DEI PRODOTTI DELLA RICERCA

PERTILE, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.395
EU - Europa 2.952
AS - Asia 1.721
SA - Sud America 238
Continente sconosciuto - Info sul continente non disponibili 87
AF - Africa 71
OC - Oceania 13
Totale 8.477
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.329
RU - Federazione Russa 950
SG - Singapore 674
IT - Italia 603
GB - Regno Unito 543
CN - Cina 483
BR - Brasile 198
DE - Germania 182
FR - Francia 166
HK - Hong Kong 162
VN - Vietnam 134
IE - Irlanda 127
SE - Svezia 121
FI - Finlandia 98
KR - Corea 62
BD - Bangladesh 52
CA - Canada 33
IN - India 32
UA - Ucraina 27
NL - Olanda 22
ES - Italia 20
JP - Giappone 19
BE - Belgio 18
PL - Polonia 18
TR - Turchia 15
ID - Indonesia 13
MX - Messico 13
AU - Australia 12
EC - Ecuador 10
NG - Nigeria 10
SA - Arabia Saudita 10
ZA - Sudafrica 10
AR - Argentina 9
CO - Colombia 9
IQ - Iraq 9
PT - Portogallo 9
TG - Togo 9
AT - Austria 8
EG - Egitto 7
IR - Iran 7
PK - Pakistan 7
BJ - Benin 6
CZ - Repubblica Ceca 6
MA - Marocco 6
TN - Tunisia 6
CR - Costa Rica 5
GR - Grecia 5
NO - Norvegia 5
CL - Cile 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
JO - Giordania 4
KZ - Kazakistan 4
LT - Lituania 4
MY - Malesia 4
TW - Taiwan 4
UG - Uganda 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CH - Svizzera 3
DK - Danimarca 3
ET - Etiopia 3
KE - Kenya 3
PY - Paraguay 3
RO - Romania 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
VE - Venezuela 3
AZ - Azerbaigian 2
BH - Bahrain 2
BY - Bielorussia 2
IL - Israele 2
LK - Sri Lanka 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
CG - Congo 1
DZ - Algeria 1
EU - Europa 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LY - Libia 1
MR - Mauritania 1
MT - Malta 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
Totale 8.388
Salva come PNG Salva come JPEG
Città #
Southend 437
Ashburn 400
Singapore 365
San Jose 351
Dallas 328
Moscow 310
Chandler 308
Woodbridge 198
Verona 167
Ann Arbor 166
Jacksonville 164
Hong Kong 157
Council Bluffs 132
Dublin 118
The Dalles 78
Los Angeles 73
Beijing 66
Milan 59
Padova 56
New York 52
Princeton 46
Lawrence 44
Houston 43
Munich 43
Wilmington 42
Ho Chi Minh City 36
Helsinki 35
Nanjing 31
Hanoi 29
Buffalo 28
Shenyang 28
Tianjin 26
Jinan 25
Santa Clara 25
São Paulo 24
Boardman 20
Frankfurt am Main 20
Orem 18
Rome 18
Tokyo 18
Warsaw 18
Montreal 17
Phoenix 17
Zhengzhou 16
Brussels 15
Guangzhou 15
Columbus 14
Hebei 14
Lancaster 14
London 13
Sindelfingen 13
Taiyuan 13
Chennai 12
Redondo Beach 12
Seattle 12
Stockholm 12
Haikou 11
Hangzhou 11
Chicago 10
Falkenstein 10
Ningbo 10
San Francisco 10
Atlanta 9
Boston 9
Denver 9
Jakarta 9
Jiaxing 9
Lomé 9
Norwalk 9
Redmond 9
Roverbella 9
Taizhou 9
Abuja 8
Changsha 8
Manchester 8
Afragola 7
Ankara 7
Bari 7
Brooklyn 7
Da Nang 7
Dong Ket 7
Haiphong 7
Meda 7
Nanchang 7
Poplar 7
Riyadh 7
Venice 7
Washington 7
Amsterdam 6
Belluno 6
Belo Horizonte 6
Biên Hòa 6
Cotonou 6
Johannesburg 6
Lanzhou 6
Limena 6
Lonigo 6
Melbourne 6
Rio de Janeiro 6
Romola 6
Totale 5.150
Salva come PNG Salva come JPEG
Nome #
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysis 278
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 269
A Large Scale OLG Model for the Analysis of the Redistributive Effects of Policy Reforms 253
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 245
A stepped-wedge randomised controlled trial to assess efficacy and cost-effectiveness of a care-bundle to prevent falls in older hospitalised patients 235
R&D and market size: who benefits from orphan drug regulation? 235
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 226
A large scale OLG model for France, Italy and Sweden: assessing the interpersonal and intrapersonal redistributive effects of public policies 214
Redistribution at the Local Level: The Case of Public Childcare in Italy. University of Verona Department of Economics Working Paper 21/2013 (ISSN 2036-2919) 201
Investimenti pubblici, risorse scarse: il ruolo dei diversi metodi di supporto alle decisioni 198
L'ISEE in Italia: una nota metodologica partendo dai dati EU-SILC. University of Verona Department of Economics Working Paper 6/2014 (ISSN 2036-2919) 190
Redistribution at the Local Level: The Case of Public Childcare in Italy 190
DRGs: the link between investment in technologies and appropriateness. WP Series University of Verona Department of Economics (ISSN 2036-2919), 31/2012 183
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 181
Dynamic, economic approaches to HTA under uncertainty. WP Series University of Verona Department of Economics (ISSN 2036-2919), 03/2011 175
Job Sick Leave: Detecting Opportunistic Behavior 173
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry 170
Public finance consolidation and fairness across living generations: the case of Italy. WP Series University of Verona Department of Economics (ISSN 2036-2919), 04/2012 168
Efficienza e sostenibilità dell’intervento pubblico 165
Improving access to medicines and promoting pharmaceutical innovation 162
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial 161
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 159
The dynamics of pharmaceutical regulation and R&D investments. WP Series University of Verona Department of Economics (ISSN 2036-2919), 4/2012 153
A reply to "Who would benefit from average value-based pricing?" 151
Dynamic, incentive-compatible contracting for health services 149
The fiscal disadvantage of young italians: a new view on consolidation and fairness 147
The timing of adoption of positron emission tomography:a real options approach 147
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 145
Two-part payments for the reimbursement of investments in health technologies 145
Strategic Interaction in Pharmaceutical Price Regulation: With or Without U? 141
Which valued-based price when patients are heterogeneous? 141
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial 141
Optimal sequential sampling rules for the economic evaluation of health technologies 140
Investment in health technologies in a competitive model with real options 139
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy 139
The dynamics of pharmaceutical regulation and R&D investments 139
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition" 138
Who should monitor job sick leave? 132
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 131
The impact of managed entry agreements on pharmaceutical prices 129
Optimal Decision Rules for HTA Under Uncertainty: a Wider, Dynamic Perspective 126
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 126
R&D and market size: who benefits from orphan drug legislation? 125
Technology adoption, quality and health care costs: a review of the literature 124
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 124
Pricing policies when patients are heterogeneous: a welfare analysis 120
L’equità intergenerazionale delle politiche di bilancio 118
Static and dynamic effciency of irreversible health care investments under alternative payment rules 115
Static and Dynamic Efficiency of Irreversible Health Care investments under Alternative Payment Rules 107
Public health interventions: evaluating the economic evaluations 107
Valutare l’efficienza dei servizi ospedalieri in Italia: il caso delle aziende ospedaliero-universitarie 96
Optimal Sequential Sampling with Delayed Observations and Unknown Variance 88
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 82
Market size and strategic interaction in pharmaceutical price regulation 23
The Price of National Pharmaceutical Pricing in the EU: A Proposal for “Common Procurement” 18
Totale 8.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.715
article - articoli 14.416
book - libri 0
conference - conferenze 441
curatela - curatele 537
other - altro 10.387
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.934
Totale 55.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022309 0 0 0 6 19 17 18 25 41 13 66 104
2022/2023804 60 96 72 122 76 194 7 53 84 12 24 4
2023/2024435 18 30 31 72 47 57 27 38 10 16 53 36
2024/20251.183 57 90 67 195 32 32 31 102 162 82 103 230
2025/20263.547 218 177 331 568 833 206 374 183 252 210 68 127
2026/2027481 82 117 160 122 0 0 0 0 0 0 0 0
Totale 8.477